KAIROS PHARMA, LTD.
NYSE: KAPA (Kairos Pharma, Ltd.)
Kemas kini terakhir: semalam, 5:38PM0.436
-0.02 (-4.60%)
| Penutupan Terdahulu | 0.457 |
| Jumlah Dagangan | 33,061 |
| Purata Dagangan (3B) | 364,385 |
| Modal Pasaran | 2,042,202 |
| Harga / Buku (P/B) | 0.420 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.09 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.26% |
| Nisbah Semasa (MRQ) | 6.77 |
| Aliran Tunai Operasi (OCF TTM) | -4.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.55 M |
| Pulangan Atas Aset (ROA TTM) | -65.65% |
| Pulangan Atas Ekuiti (ROE TTM) | -110.77% |
AISkor Stockmoo
| Nilai 30% | 0.0 |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -5.0 |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 20% | -4.0 |
| Institusi bersih -3.72% daripada saham dalam pemfailan 13F terkini: 5 pemegang menambah, 11 mengurang (suku berakhir 30 Sep 2026). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham kebanyakannya menurun. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. info | |
| Skor Akhir | -3.26 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Kairos Pharma, Ltd. | - | - |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| KAPA | 2 M | - | - | 0.420 | -3.3 |
| CYBN | 359 M | - | - | - | 0.0 |
| NRXS | 60 M | - | - | 18.58 | -1.2 |
| CVM | 21 M | - | - | 2.22 | -3.7 |
| NHWK | 20 M | - | - | 0.260 | 0.0 |
| AEON | 10 M | - | - | - | -3.3 |
|
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 24.29% |
| % Dimiliki oleh Institusi | 3.45% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aptus Capital Advisors, Llc | 30 Sep 2026 | 0 |
| Sevenbridge Financial Group, Llc | 30 Sep 2026 | 0 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 1.20%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 5 | 14,551 |
| Berkurang | 11 | 115,458 |
| Baharu | 2 | 4,680 |
| Dijual habis | 9 | 89,782 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Nov 2026 | Yahoo Finance |
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
LOS ANGELES, November 05, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for… |
| 03 Nov 2026 | Yahoo Finance |
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
LOS ANGELES, November 03, 2026--Neil Bhowmick, President and CSO of Kairos Pharma, presents on lead candidate ENV-105 and its interim efficacy results at Cancer R&D 2026… |
| 22 Oct 2026 | Yahoo Finance |
CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular… |
| 06 Oct 2026 | Yahoo Finance |
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
LOS ANGELES, October 06, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with… |
| 23 Sep 2026 | Yahoo Finance |
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the… |
| 09 Sep 2026 | Yahoo Finance |
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global… |
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |